SWISS drug ingredients maker Lonza Group is maintaining its full-year outlook amid positive momentum in its core healthcare businesses and headwinds in its speciality ingredients segment, the...

SWISS drug ingredients maker Lonza Group is maintaining its full-year outlook amid positive momentum in its core healthcare businesses and headwinds in its speciality ingredients segment, the...

SWISS drug ingredients maker Lonza Group's fiscal 2018 net profit fell 20.9 per cent to 559 million Swiss francs (S$757.4 million) from the previous year's 707 million francs, on the...

SWISS biotech Lonza Group announced on Thursday afternoon that Standard & Poor's (S&P) has assigned it a BBB+ credit rating with stable outlook....